| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC0901 |
| Trial ID | ChiCTR2000041012 |
| Disease | Multiple Myeloma |
| Altered gene | CD19|BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | BCMA/CD19 CAR-T cells |
| Phase | Early_Phase1 |
| Recruitment status | Recruiting |
| Title | Clinical study on the safety and effectiveness of targeting CD19 and BCMA CAR - T cells immunotherapy in patients with relapsed or refractory multiple myeloma |
| Year | 2020 |
| Country | China |
| Company sponsor | Shanxi Cancer Hospital |
| Cohort 1 | |||||||||
|
|||||||||